Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 5Completed 5Active not recruiting 2Recruiting 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 46Gynecologic 12CNS 8Tumor-Agnostic 5Sarcoma 5Genitourinary 2Thoracic 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 1

Interventions

Oxaliplatin 197Bevacizumab 162Fluorouracil 155Capecitabine 137Gemcitabine 133Leucovorin 112pembrolizumab 99Cisplatin 93Drug Therapy 89Irinotecan 81Radiotherapy 73sintilimab 70durvalumab 65130-nm albumin-bound paclitaxel 65Paclitaxel 64Specimen Handling 62Cetuximab 61lenvatinib 59tislelizumab 58Nivolumab 55Magnetic Resonance Spectroscopy 55Folfox protocol 55Blood Specimen Collection 52atezolizumab 48Biopsy 46Surgical Procedures, Operative 40Taxes 38Albumin-Bound Paclitaxel 38Immune Checkpoint Inhibitors 37HMPL-013 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × abemaciclib × Gastrointestinal × Clear all
NCT06654037 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
39 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡